Lilly's $3.2B Morphic Buy Enhances IBD Therapeutics Pipeline

Eli Lilly has agreed to acquire Morphic for $3.2 billion, securing control of an oral, midphase alternative to Takeda's injectable inflammatory bowel disease drug, Entyvio. Morphic's leading candidate, MORF-057, is an oral small molecule that inhibits α4β7 integrin, which plays a crucial role in controlling intestinal inflammation in conditions like ulcerative colitis and Crohn's disease. The convenience of an oral medication makes MORF-057 a formidable challenger to Entyvio, which has become a major product for Takeda.

Morphic's MORF-057 is in phase 2 development, having entered this stage in 2022, which is over a year ahead of Gilead Sciences' similar candidate. This move follows Lilly's previous acquisition of a preclinical oral α4β7 program from Dice Therapeutics for $2.4 billion, highlighting its strategic focus on this therapeutic area.

Other competitors, such as Ensho Therapeutics and Protagonist Therapeutics, have also been active in developing oral α4β7 inhibitors. While Ensho has a phase 2-ready candidate, Protagonist abandoned its first oral α4β7 antagonist after disappointing phase 2b results and later dropped a second-generation prospect despite initially positive data.

Morphic initially showed promising results with MORF-057, reporting a clinical remission rate comparable to Entyvio, which excited investors. However, subsequent data revealing less than expected endoscopic improvement led to a decline in Morphic's stock price. Lilly's offer of $57 per share represents an 87% premium over the 30-day average trading price, valuing Morphic at $3.2 billion, which is about the same as its peak post-phase 2a data release value in April 2023.

The success of Lilly's investment will become clearer in the first half of next year when phase 2b trial results for ulcerative colitis are expected. Additionally, Morphic's phase 2 trial for Crohn's disease, which began in April, aims for primary completion in 2026, potentially solidifying MORF-057's place as a significant oral competitor in the inflammatory bowel disease treatment market.

Lilly was also featured recently for their partnership with Radionetics Oncology, read here.

Click here to read the original news story.